CG Oncology (CGON) Intangibles (2025 - 2026)

CG Oncology's (CGON) quarterly Intangibles came in at $560000.0 in Q1 2026, down 2.61% on a QoQ basis from $575000.0 in Q4 2025.

Analysis

CG Oncology (CGON) Intangibles (2025 - 2026) Analysis & Trends

CG Oncology (CGON) has 2 years of Intangibles data on file, last reported at $560000.0 in Q1 2026.

Quarterly Intangibles changed N/A year-over-year to $560000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $560000.0 (changed N/A YoY) and the FY2025 annual result came in at $575000.0, changed N/A from the prior year.
Intangibles slipped to $560000.0 in Q1 2026, from $575000.0 in the prior quarter.
In the past five years, Intangibles ranged from a high of $1.7 million in Q3 2025 to a low of $560000.0 in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn	-
5	Revolution Medicines	44.04 Bn	44.04 Bn	-	63.28 Mn
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn	60.96 Mn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn	-
8	Royalty Pharma	28.41 Bn	27.57 Bn	-	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	93.49 Mn
10	CG Oncology	6.56 Bn	6.56 Bn	-2.77 Mn	545,000.00

Historic Data

Download Data